Switch theme
Sign up to access all valuation multiples
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
2013
71
LTM Revenue $10.1M
LTM EBITDA n/a
$50.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verrica Pharmaceuticals has a last 12-month revenue of $10.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Verrica Pharmaceuticals achieved revenue of $7.6M and an EBITDA of -$65.9M.
Verrica Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verrica Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.1M | $7.6M | XXX | XXX | XXX |
| Gross Profit | $8.3M | $4.4M | XXX | XXX | XXX |
| Gross Margin | 162% | 58% | XXX | XXX | XXX |
| EBITDA | -$62.2M | -$65.9M | XXX | XXX | XXX |
| EBITDA Margin | -1214% | -871% | XXX | XXX | XXX |
| Net Profit | -$24.5M | -$67.0M | XXX | XXX | XXX |
| Net Margin | -478% | -885% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Verrica Pharmaceuticals's stock price is $1.
Verrica Pharmaceuticals has current market cap of $50.7M, and EV of $50.4M.
See Verrica Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50.4M | $50.7M | XXX | XXX | XXX | XXX | $-1.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Verrica Pharmaceuticals has market cap of $50.7M and EV of $50.4M.
Verrica Pharmaceuticals's trades at 5.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Verrica Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Verrica Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $50.4M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVerrica Pharmaceuticals's NTM/LTM revenue growth is 106%
Verrica Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Verrica Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Verrica Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Verrica Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 48% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -871% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -765% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 156% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 934% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verrica Pharmaceuticals acquired XXX companies to date.
Last acquisition by Verrica Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Verrica Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Verrica Pharmaceuticals founded? | Verrica Pharmaceuticals was founded in 2013. |
| Where is Verrica Pharmaceuticals headquartered? | Verrica Pharmaceuticals is headquartered in United States of America. |
| How many employees does Verrica Pharmaceuticals have? | As of today, Verrica Pharmaceuticals has 71 employees. |
| Who is the CEO of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's CEO is Dr. Jayson Rieger. |
| Is Verrica Pharmaceuticals publicy listed? | Yes, Verrica Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Verrica Pharmaceuticals? | Verrica Pharmaceuticals trades under VRCA ticker. |
| When did Verrica Pharmaceuticals go public? | Verrica Pharmaceuticals went public in 2018. |
| Who are competitors of Verrica Pharmaceuticals? | Similar companies to Verrica Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's current market cap is $50.7M |
| What is the current revenue of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's last 12-month revenue is $10.1M. |
| What is the current EV/Revenue multiple of Verrica Pharmaceuticals? | Current revenue multiple of Verrica Pharmaceuticals is 5.0x. |
| What is the current revenue growth of Verrica Pharmaceuticals? | Verrica Pharmaceuticals revenue growth between 2023 and 2024 was 48%. |
| Is Verrica Pharmaceuticals profitable? | Yes, Verrica Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
